Overview

Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer

Status:
Completed

Trial end date:
2017-06-15

Target enrollment:

Participant gender:

Summary

This is an open-label Phase 1b dose-escalation study to assess the safety, tolerability, and PK of OMP-54F28 when combined with nab-paclitaxel and gemcitabine. OMP-54F28 will be administered IV on Days 1 and 15 of each 28-day cycle. Nab-paclitaxel (125 mg/m2) and gemcitabine (1000 mg/m2) will be administered IV on Days 1, 8, and 15 of each cycle. The planned dose levels of OMP-54F28 are 3.5 mg/kg and 7.0 mg/kg.

Phase:

Phase 1

Details

Lead Sponsor:

OncoMed Pharmaceuticals, Inc.

Treatments:

Albumin-Bound Paclitaxel
Gemcitabine
Immunoglobulin Fc Fragments
Paclitaxel